Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

ClinicalTrials.gov ID: NCT01431638

Public ClinicalTrials.gov record NCT01431638. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

Study identification

NCT ID
NCT01431638
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
397 participants

Conditions and interventions

Interventions

  • Canakinumab 150mg in prefilled syringe Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 24, 2011
Primary completion
May 8, 2013
Completion
May 8, 2013
Last update posted
Jul 18, 2021

2011 – 2013

United States locations

U.S. sites
54
U.S. states
23
U.S. cities
53
Facility City State ZIP Site status
Novartis Investigative Site Anniston Alabama 36207-5710
Novartis Investigative Site Gulf Shores Alabama 36547
Novartis Investigative Site Mobile Alabama 36608
Novartis Investigative Site Chandler Arizona 85224
Novartis Investigative Site Scottsdale Arizona 85251
Novartis Investigative Site Buena Park California 90620
Novartis Investigative Site Norwalk California 90650
Novartis Investigative Site Westlake Village California 91361
Novartis Investigative Site Jupiter Florida 33458
Novartis Investigative Site Largo Florida 33773
Novartis Investigative Site South Miami Florida 33143
Novartis Investigative Site Augusta Georgia 30904
Novartis Investigative Site Decatur Georgia 30035
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Louisville Kentucky 40217
Novartis Investigative Site Owensboro Kentucky 42303
Novartis Investigative Site Metairie Louisiana 70006
Novartis Investigative Site Troy Michigan 48085
Novartis Investigative Site Belzoni Mississippi 39038
Novartis Investigative Site Jackson Mississippi 39209
Novartis Investigative Site Picayune Mississippi 39466
Novartis Investigative Site Missoula Montana 59804
Novartis Investigative Site Lincoln Nebraska 68516
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative Site Omaha Nebraska 68134
Novartis Investigative Site Mineola New York 11501
Novartis Investigative Site New Hyde Park New York 11042
Novartis Investigative Site Roslyn New York 11576
Novartis Investigative Site Asheville North Carolina 28801
Novartis Investigative Site Cary North Carolina 27518
Novartis Investigative Site Charlotte North Carolina 28209
Novartis Investigative Site Greensboro North Carolina 27401
Novartis Investigative Site Salisbury North Carolina 28144
Novartis Investigative Site Shelby North Carolina 28152
Novartis Investigative Site Wilmington North Carolina 28401
Novartis Investigative Site Fargo North Dakota 58103
Novartis Investigative Site Mogadore Ohio 44260
Novartis Investigative Site Duncansville Pennsylvania 16635
Novartis Investigative Site Charleston South Carolina 29412
Novartis Investigative Site Columbia South Carolina 29204
Novartis Investigative Site Fort Mill South Carolina 29707
Novartis Investigative Site Greer South Carolina 29651
Novartis Investigative Site Varnville South Carolina 29944
Novartis Investigative Site Bristol Tennessee 37620
Novartis Investigative Site Johnson City Tennessee 37601
Novartis Investigative Site Memphis Tennessee 38125
Novartis Investigative Site Bedford Texas 76021
Novartis Investigative Site Dallas Texas 75231
Novartis Investigative Site League City Texas 77573
Novartis Investigative Site Bountiful Utah 84010
Novartis Investigative Site Danville Virginia 24541
Novartis Investigative Site Midlothian Virginia 23114
Novartis Investigative Site Newport News Virginia 23606
Novartis Investigative Site Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01431638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01431638 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →